Maravai LifeSciences
MRVI
160 hedge funds and large institutions have $375M invested in Maravai LifeSciences in 2025 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 46 increasing their positions, 47 reducing their positions, and 18 closing their positions.
4,967% more call options, than puts
Call options by funds: $3.19M | Put options by funds: $63K
61% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 18
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
20% more capital invested
Capital invested by funds: $313M → $375M (+$62.5M)
7% more funds holding
Funds holding: 150 → 160 (+10)
0.28% more ownership
Funds ownership: 90.07% → 90.36% (+0.28%)
2% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$8.97M |
| 2 |
MAM
Monaco Asset Management
Monaco
|
+$7.09M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$2.53M |
| 4 |
TC
Tejara Capital
London,
United Kingdom
|
+$1.31M |
| 5 |
RA
Royce & Associates
New York
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.76M |
| 2 |
PD
Point72 (DIFC)
Dubai,
United Arab Emirates
|
-$2.89M |
| 3 |
I
Immersion
Aventura,
Florida
|
-$2.39M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.13M |
| 5 |
BlackRock
New York
|
-$1.51M |
MRVI Hedge Fund Activity: Q3 2025 in Review
160 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q3 2025, worth a combined $375M — up 20% from $313M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new MRVI positions and 18 closed out — a net gain of 11 holders — while 46 added to existing stakes and 47 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $8.97M. The largest seller was Vanguard Group, cutting an estimated $5.76M.
- 160 institutional investors held Maravai LifeSciences (MRVI) as of Q3 2025, up from 150 in Q2 2025.
- Funds reported $375M of Maravai LifeSciences stock for Q3 2025, up 20% quarter-over-quarter.
- 29 funds opened new Maravai LifeSciences positions in Q3 2025 and 18 closed out, a net change of +11 holders.
- The largest Maravai LifeSciences buyer in Q3 2025 was T. Rowe Price Investment Management, an estimated $8.97M added.
- The largest Maravai LifeSciences seller in Q3 2025 was Vanguard Group, an estimated $5.76M sold.
Based on aggregated 13F filings for Q3 2025.